Fisher & Paykel Healthcare (NZSE:FPH) Long-Term Capital Lease Obligation : NZ$0 Mil (As of Sep. 2023)

View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare Long-Term Capital Lease Obligation?

Fisher & Paykel Healthcare's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was NZ$0 Mil.

Fisher & Paykel Healthcare's quarterly Long-Term Capital Lease Obligation increased from Sep. 2022 (NZ$0 Mil) to Mar. 2023 (NZ$45 Mil) but then declined from Mar. 2023 (NZ$45 Mil) to Sep. 2023 (NZ$0 Mil).

Fisher & Paykel Healthcare's annual Long-Term Capital Lease Obligation declined from Mar. 2021 (NZ$29 Mil) to Mar. 2022 (NZ$24 Mil) but then increased from Mar. 2022 (NZ$24 Mil) to Mar. 2023 (NZ$45 Mil).

Fisher & Paykel Healthcare Long-Term Capital Lease Obligation Historical Data

The historical data trend for Fisher & Paykel Healthcare's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare Long-Term Capital Lease Obligation Chart

Fisher & Paykel Healthcare Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

22.00

29.00

24.30

45.40

Fisher & Paykel Healthcare Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	24.30	-	45.40	-

Fisher & Paykel Healthcare (NZSE:FPH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Fisher & Paykel Healthcare Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

FSPKF:USA FPLB:Germany FPH:Australia

Address

15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013

Website

https://www.fphcare.com

Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.